Stryker (NYSE:SYK) will post its quarterly earnings results after the market closes on Thursday, April 26th. Analysts expect Stryker to post earnings of $1.60 per share for the quarter. Stryker has set its Q1 guidance at $1.57-1.62 EPS and its FY18 guidance at $7.07-7.17 EPS.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the previous year, the firm earned $1.78 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. On average, analysts expect Stryker to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.
NYSE SYK opened at $164.71 on Wednesday. Stryker has a 52 week low of $131.67 and a 52 week high of $170.00. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29. The firm has a market cap of $61,534.95, a PE ratio of 25.38, a P/E/G ratio of 2.36 and a beta of 0.70.
Several research analysts have recently commented on the company. Zacks Investment Research upgraded Stryker from a “sell” rating to a “hold” rating and set a $177.00 price target on the stock in a report on Thursday, April 12th. Evercore ISI assumed coverage on Stryker in a report on Monday, April 2nd. They set an “in-line” rating and a $165.00 price target on the stock. Raymond James assumed coverage on Stryker in a report on Thursday, March 15th. They set an “outperform” rating and a $183.00 price target on the stock. ValuEngine upgraded Stryker from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, Citigroup upgraded Stryker from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $165.77 to $166.00 in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and sixteen have issued a buy rating to the company. Stryker currently has a consensus rating of “Buy” and a consensus price target of $165.27.
In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of Stryker stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Glenn S. Boehnlein sold 750 shares of Stryker stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $160.00, for a total value of $120,000.00. Following the completion of the transaction, the chief financial officer now directly owns 3,535 shares of the company’s stock, valued at $565,600. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 145,890 shares of company stock worth $24,045,900. 7.30% of the stock is owned by insiders.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.